

LIVEWELL™



PATH TO PEPTIDES THE GLP-1 PILL IS HERE:

NO MORE NEEDLES?

**Oral Wegovy just got FDA-approved.
Orforglipton is next. Welcome to the pill era.**

FOR RESEARCH AND EDUCATIONAL PURPOSES ONLY

THE END OF THE NEEDLE ERA?

For years, the biggest complaint about GLP-1 medications was simple: nobody likes shots. Weekly injections kept millions of people from even trying these drugs. That barrier just came down.

In December 2025, the FDA approved oral Wegovy — the first-ever GLP-1 pill for weight loss. One pill a day. No needles. No refrigeration. And Eli Lilly's orforglipron could get the green light by mid-2026.

This is one of the biggest shifts in obesity medicine in decades.

THE BIG NUMBER

In the OASIS 4 trial, oral semaglutide 25 mg produced 16.6% average weight loss at 64 weeks — nearly matching the injectable version. One-third of people lost 20% or more of their body weight.¹

HOW THE ORAL PILL WORKS

Getting a peptide drug to survive your stomach acid is like mailing a letter through a shredder. Your digestive system is designed to break peptides apart.

Novo Nordisk solved this with a clever trick. The Wegovy pill contains a special absorption enhancer called SNAC. Think of it as a bodyguard that protects the semaglutide molecule and helps it slip through your stomach lining into your bloodstream.²

The catch? You have to take it on an empty stomach with just a small sip of water, then wait 30 minutes before eating or drinking anything else.

ORFORGLIPRON: THE NO-RULES PILL

Eli Lilly's orforglipron takes a completely different approach. Instead of being a peptide (which gets destroyed by stomach acid), it's a small molecule – a chemical designed to mimic what GLP-1 does without actually being GLP-1.3

The advantage? No food or water restrictions. Take it any time. With food or without. That's a huge deal for real-world convenience.

Feature	Oral Wegovy (Semaglutide)	Orforglipron (Eli Lilly)	Injectable Wegovy
FDA Status	Approved Dec 2025	Under FDA Review	Approved 2021
Avg Weight Loss	13.6-16.6%	7.5-12.4%	14.9-16.8%
Dosing	Once daily	Once daily	Once weekly shot
Food Restrictions	Yes — empty stomach	None	None
Self-Pay Price	\$149/month	Est. \$149-\$399	\$350/month

WHY THIS CHANGES EVERYTHING

Research shows that **roughly half of GLP-1 users stop within a year.**⁴ Needle anxiety is one of the top reasons. An effective pill could dramatically improve long-term adherence.

The ATTAIN-MAINTAIN trial showed that orforglipron can help people **maintain weight loss** after switching from injectable GLP-1s — meaning pills could serve as a long-term maintenance strategy.⁵

Both Novo Nordisk and Eli Lilly have committed to affordable pricing. Oral Wegovy launches at **\$149/month** for self-pay patients. Lilly has announced orforglipron could start at \$149 for the lowest dose.⁶

THE BOTTOM LINE

The GLP-1 pill revolution is here. Oral Wegovy is FDA-approved and available. Orforglipron could follow by mid-2026. While pills may produce slightly less weight loss than injections, the convenience factor could help millions more people access and stick with treatment. Talk to your doctor about which option is right for you.

REFERENCES

1. Wharton S, et al. OASIS 4: Oral semaglutide 25 mg in adults with overweight/obesity. *NEJM*. 2025.
2. Buckley ST, et al. Transcellular stomach absorption of a derivatized GLP-1 peptide. *Science Translational Medicine*. 2018.
3. Eli Lilly. What to Know About Orforglipron. *Lilly.com*, 2026.
4. Nagendra L, et al. GLP-1 RA discontinuation rates. *Diabetes Obes Metab*. 2024.
5. Eli Lilly. ATTAIN-MAINTAIN topline results. Press release, December 2025.
6. Novo Nordisk. Wegovy pill approved in the US. Press release, December 22, 2025.
7. FDA. Approval of oral semaglutide for weight management. December 2025.
8. Lilly. Orforglipron superior to oral semaglutide in ACHIEVE-3 trial. September 2025.
9. FDA. Commissioner's National Priority Review Voucher. November 2025.
10. Prime Therapeutics. GLP-1 Pipeline Update. November 2025.
11. AJMC. FDA Approves Oral Semaglutide as First GLP-1 Pill. February 2026.
12. Knop FK, et al. Oral semaglutide pharmacokinetics. *Lancet Diabetes Endocrinol*. 2023.

REFERENCES

1. Wharton S, et al. OASIS 4: Oral semaglutide 25 mg in adults with overweight/obesity. *NEJM*. 2025.
2. Buckley ST, et al. Transcellular stomach absorption of a derivatized GLP-1 peptide. *Science Translational Medicine*. 2018.
3. Eli Lilly. What to Know About Orforglipron. *Lilly.com*, 2026.
4. Nagendra L, et al. GLP-1 RA discontinuation rates. *Diabetes Obes Metab*. 2024.
5. Eli Lilly. ATTAIN-MAINTAIN topline results. Press release, December 2025.
6. Novo Nordisk. Wegovy pill approved in the US. Press release, December 22, 2025.
7. FDA. Approval of oral semaglutide for weight management. December 2025.
8. Lilly. Orforglipron superior to oral semaglutide in ACHIEVE-3 trial. September 2025.
9. FDA. Commissioner's National Priority Review Voucher. November 2025.
10. Prime Therapeutics. GLP-1 Pipeline Update. November 2025.
11. AJMC. FDA Approves Oral Semaglutide as First GLP-1 Pill. February 2026.
12. Knop FK, et al. Oral semaglutide pharmacokinetics. *Lancet Diabetes Endocrinol*. 2023.

FOR RESEARCH AND EDUCATIONAL PURPOSES ONLY

This document is intended solely for educational purposes to increase awareness of emerging scientific research. It does not constitute medical advice.

Regulatory Status: Oral semaglutide (Wegovy 25 mg) is FDA-approved for chronic weight management and cardiovascular risk reduction.

Orforglipron is investigational and not yet FDA-approved. All healthcare decisions should be made in consultation with qualified medical professionals.



LIVEWELL™

